Taizhou, China

Fei Deng

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Zhejiang Hisoar Pharmaceutical Co., Ltd.. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fei Deng. Retrieved from https://idiyas.com/inventor/fei-deng-s4jo604j

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fei Deng: Innovator in Pharmaceutical Chemistry

Introduction

Fei Deng is a notable inventor based in Taizhou, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative processes for synthesizing important medications.

Latest Patents

Fei Deng holds a patent for "Intermediates of sitagliptin and preparation process thereof." This patent discloses intermediates of Sitagliptin, a preparation process thereof, and a method for synthesizing Sitagliptin using these intermediates. The synthesis of Sitagliptin is achieved by utilizing chiral amino compounds as raw materials, eliminating the need to build a chiral center through chiral asymmetric catalytic hydrogenation, and avoiding high-pressure hydrogenation.

Career Highlights

Fei Deng is currently associated with Zhejiang Hisoar Pharmaceutical Co., Ltd., where he applies his expertise in pharmaceutical development. His work focuses on enhancing the efficiency and effectiveness of drug synthesis processes.

Collaborations

Fei Deng collaborates with Xianhua Pan, contributing to advancements in their field through shared knowledge and expertise.

Conclusion

Fei Deng's innovative work in the synthesis of Sitagliptin showcases his commitment to improving pharmaceutical processes. His contributions are vital to the ongoing development of effective medications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…